- Home
- NVCR vs OGN Comparison
NVCR vs OGN Comparison
Compare NVCR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | OGN |
|---|---|---|
| Founded | 2000 | 1923 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVCR | OGN |
|---|---|---|
| Price | $10.51 | $7.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $26.42 | $14.10 |
| AVG Volume (30 Days) | 1.4M | ★ 6.2M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 1.01% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | $642,269,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $10.64 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | ★ N/A | $4.14 |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $9.82 | $6.18 |
| 52 Week High | $22.95 | $17.23 |
Technical Indicators
Market Signals| Indicator | NVCR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 41.94 |
| Support Level | $9.82 | $7.74 |
| Resistance Level | $12.91 | $8.48 |
| Average True Range (ATR) | 0.62 | 0.42 |
| MACD | -0.33 | -0.17 |
| Stochastic Oscillator | 13.91 | 6.59 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.